目的: 对高血压患者经治疗干预后的收缩压降低与心血管系统长期健康获益及医疗费用降低的数值关系进行计算分析,为新医药技术的价值评估、合理定价和临床应用提供有效的决策依据。方法: 基于高血压疾病进程建立马尔科夫模型,对收缩压（SBP）降低后的长期心血管事件风险进行分析,从而对可得的质量调整生命年(QALYs)增量和相关医疗费用降低量进行计算,并开展影响因素的敏感性分析。结果: 经治疗干预后,男性高血压患者SBP每降低1mmHg,平均可获得0.0047个增量QALYs并节约319.34元;女性高血压患者SBP每降低1mmHg,平均可获得0.0035个增量QALYs并节约219.97元,敏感性分析提示研究结果稳健。结论: 降低高血压患者的收缩压能带来明确的心血管健康获益和费用节约,阐明其数量关系可有效地支持相关卫生决策。
Abstract
Objective: The paper calculates and analyzes the numerical relationship between systolic blood pressure (SBP) reduction in hypertension patients after treatment intervention with long-term cardiovascular health benefit and medical cost saving, providing an effective decision-making basis for the value evaluation, reasonable pricing, and clinical application of new pharmaceutical technologies. Methods: Based on disease progression of hypertension, a Markov model was established to analyze the improvement of long-term cardiovascular risks due to SBP reduction, and consequently to calculate the incremental quality-adjusted life years (QALYs) and medical cost saving. Sensitivity analysis was conducted. Results: After treatment intervention, for male hypertension patients, 1mmHg reduction in SBP could bring 0.0047 incremental QALYs and 319.34 yuan of cost saving; for hypertension patients, 1mmHg reduction in SBP could bring 0.0035 incremental QALYs and 219.97 yuan of cost saving. Sensitivity analysis suggested the results were robust. Conclusion: SBP reduction in hypertension patients could bring clear long-term health benefits and cost-saving. The numerical results could be used to support healthcare decision-making.
关键词
慢病管理 /
健康获益 /
医疗费用
Key words
chronic disease management /
health benefits /
medical costs
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants[J]. Lancet, 2021,398(10304):957-980.
[2] 赵冬. 中国成人高血压流行病学现状[J].中国心血管杂志,2020,25(06):513-515.
[3] 刘明波,何新叶,杨晓红,等.《中国心血管健康与疾病报告2023》要点解读[J].临床心血管病杂志,2024,40(08):599-616.
[4] CHOBANIAN A V, BAKRIS G L, BLACK H R, et al.Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure[J]. Hypertension, 2003, 42(6): 1206-1252.
[5] ETTEHAD D,EMDIN C A. KIRAN A, et al.Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis[J]. Lancet, 2016, 387(10022):957-967.
[6] VERDECCHIA P, GENTILE G, ANGELI F, et al.Influence of blood pressure reduction on composite cardiovascular endpoints in clinical trials[J]. Journal of hypertension, 2010, 28(7):1356-1365.
[7] EKMAN M, BIENFAIT-BEUZON C, JACKSON J.Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden[J]. Journal of human hypertension, 2008, 22:845-855.
[8] D'AGOSTINO R B, VASAN R S, PENCINA M J, et al. General cardiovascular risk profile for use in primary care: the Framingham heart study[J]. Circulation, 2008, 117(6): 743-753.
[9] 胡宏飞,周挺,李冯,等.健康价值评估中质量调整生命年的替代及优化方法介绍与比较[J].中国新药杂志,2024,33(19):1969-1975.
[10] GROSSO A M, BODALIA P N, MACALLISTER RJ, et al.Comparative clinical-and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta-and cost-utility analysis[J]. International journal of clinical practice, 2011, 65(3):253-263.
[11] 刘国恩. 中国药物经济学评价指南[M].北京:中国市场出版社,2020:16-17.
[12] 田葳. 高血压患者门诊费用及影响因素分析[D].沈阳:沈阳医学院,2022.
[13] 陈静晗. 基于Markov模型对高血压治疗药物的药物经济学评价[D].桂林:桂林电子科技大学,2022.
[14] 段承阿鑫,隋宾艳,艾丹丹,等.阿利沙坦酯治疗原发性高血压的临床综合评价[J].中国合理用药探索,2022,19(03):46-55.
[15] 刘叶倩,赵艳蛟,陈永法.2021—2023年我国药物经济学评价研究述评[J].卫生经济研究,2024,41(08):20-22+26.
[16] 陶立波. 质量与信任:在我国开展与应用医药经济学评价的策略探讨[J].中国医疗保险,2017(06):53-56.
[17] D'AGOSTINO R B, WOLF P A, BELANGER A J, et al. Stroke risk profile: adjustment for antihypertensive medication[J]. Stroke, 1994, 25(1):40-43.
[18] 吴红红,段磊,山努佳,等.老年高血压患者脉压差对肾脏损害的影响研究[J].中国全科医学,2011,14(18):2022-2024.
